Objective To explore the medical decision level diagnosed pancreatitis of urinary trypsinogen -2, and e-valuate the reliability of the positive limit (50 μg/L) of trypsinogen-2 as a diagnosed medical decision level on the pancreatitis diagnosis, avoiding its misdiagnosis.Methods 175 cases of patients visiting our hospital from July , 2010 to August, 2011 and healthy people were chosen as the research objects.We collected the first diagnosis information of the patients , detected the con-centrations of urinary trypsinogen -2 and the concentrations of serum and urine amylase , and made a diagnosis of pancreases based on the results along with CT scan data and the clinical symptoms.We grouped the patients according to the first diagnosed disease type , and then we statistically analyzed differences of concentration of urinary trypsinogen -2 between disease group and healthy group and the misdiagnosis rate as pancreatitis in each group according to urinary trypsinogen -2 positive limit.Results The concentrations of urinary trypsinogen -2 in pancreatitis group was significantly lower than that in renal dysfunction group , but was significantly higher than that in healthy group ( P<0.05 ) , and was no statistical significance compared with digestive tract ulcer group and tumor group ( P>0.05 ) .Using the urinary trypsinogen -2 positive limit as diagnosis criteria for pancreatitis , the misdiagnosis rate in the Peptic ulcer group , tumor group, renal dysfunction group were 100.00%, 77.06%, 98.00%re-spectively.Conclusion It was fit to regard the positive limit of urinary trypsinogen -2 reported in the literature as medical deci-sion of awaiting diagnosis as pancreatitis , but not as the medical decision level making a definite diagnosis as pancreatitis .It was difficult to confirm the medical decision level diagnosing pancreatitis of urinary trypsinogen -2.The value of urinary trypsinogen -2 for diagnosing pancreatitis needed to be objectively evaluated by expanding the diseases species unrelated to pancreatitis for large sample investigation.%目的：探讨尿胰蛋白酶原2（ TPS-2）诊断胰腺炎的医学决定水平，评价其阳性界值（50μg/L）作为诊断胰腺炎的确诊医学决定水平的可靠性，避免由此带来的误诊。方法选取我院2010年7月-2011年8月部分就诊患者及健康人群175例为研究对象，收集就诊患者的首诊疾病资料，对研究对象同时进行尿TPS-2、血尿淀粉酶定量测定，结合CT扫描资料及临床症状，判断患者是否患有胰腺炎；按就诊患者首诊疾病种类分组，统计分析包括胰腺炎的各类疾病组及健康人群组间尿TPS-2的浓度差异及各组按尿TPS-2的阳性界值诊断胰腺炎的误诊率。结果胰腺炎组的尿TPS-2浓度低于肾功能损害组，但高于健康人群组，差异均有统计学意义（ P＜0.05），而与消化道溃疡组、恶性肿瘤组比较差异无统计学意义（ P＞0.05）；以尿TPS-2的阳性界值诊断胰腺炎，在消化道溃疡组、肿瘤组、肾功能损害组的误诊率分别为：100.00％、77.06％、98.00％。结论文献报道的尿TPS-2的阳性界值作为胰腺炎的待诊医学决定水平较为合适，不能作为胰腺炎的确诊医学决定水平。尿TPS-2诊断胰腺炎的确诊医学决定水平确定较为困难。尿TPS-2诊断胰腺炎的客观价值还需扩大无关疾病调查种类，进行大样本调查进行盲评。
展开▼
